METHOD FOR COMBINED TREATMENT OF METASTATIC COLORECTAL CANCER IN PATIENTS WITH RESECTABLE HEPATIC METASTASES AND IN PRESENCE OF MUTATIONS IN KRAS AND BRAF GENES Russian patent published in 2021 - IPC A61K31/4375 A61K31/282 A61K31/519 A61K31/513 A61K39/395 A61P35/00 A61P35/04 

FIELD: medicine.

SUBSTANCE: invention relates to the field of medicine, namely to oncology, and can be used for combined treatment of metastatic colorectal cancer in patients with resectable hepatic metastases and in the presence of mutations in the KRAS and BRAF genes. The method includes drop administration of bevacizumab 5 mg/kg intravenously on day 1, irinotecan 165 mg/m² intravenously on day 1, oxaliplatin 85 mg/m² intravenously on day 1, leucovorin 200 mg/m² intravenously on day 1, and 5-fluorouracil 3,200 mg/m² intravenously. Three courses of preoperative treatment are conducted, wherein leucovorin infusion is conducted on days 1 and 2 at a dose of 200 mg/m², 5-fluorouracil is administered for 46 hours, the interval between the courses is 12 days. After completing the preoperative treatment, in the presence of an objective tumour response, simultaneous radical surgery is performed on the primary tumour and on the metastatic foci in the liver R0, 3 courses of adjuvant treatment are conducted in the postoperative period according to the previous scheme, but without administering bevacizumab.

EFFECT: use of the invention provides a possibility of improving the results of combined treatment of metastatic colorectal cancer with isolated liver damage by increasing the frequency of objective responses of the tumour and reducing the amount of adverse events during medicinal anti-tumour treatment, increasing the frequency of performing parenchyma-preserving radical liver resections (R0), as well as increasing the overall and relapse-free survival of patients.

1 cl, 2 ex